The research-grade biosimilar is a recombinant fully human IgG1 monoclonal antibody that specifically binds to soluble human B lymphocyte stimulator protein (BLyS), also known as B-cell activating factor (BAFF). BAFF belongs to the superfamily of Tumor Necrosis Factor (TNF) and plays a vital role in B-cell maturation and survival. It is produced by several cell types such as neutrophils, dendritic cells, and macrophages. Binding of BLyS to its receptors on the surface of B-cells activates downstream signaling pathways such as NF-κB and MAPK pathways that promote the expression of anti-apoptotic proteins and inhibit apoptosis. The antibody binds to BLyS, prevents the association with its receptors, and thereby reduces the survival of autoantibody-producing B-cells. The original drug received approval from the FDA to treat systemic lupus erythematosus.
In PBS, pH 7.5